Cytoplasmic translocation of nuclear lysine-specific demethylase-1 (LSD1/KDM1A) in human hepatoma cells is induced by its inhibitors
Abstract
Histone-modifiable lysine-specific demethylase-1 (LSD1/KDM1A) is often upregulated in many cancers, including hepatoma, and is regarded as oncoprotein. We previously reported that the hepatoma-preventive geranylgeranoic acid (GGA) inhibits KDM1A activity at the same IC50 as that of the clinically used drug tranylcypromine, a verified inhibitor of KDM1A. Here, we report that these inhibitors induced cytoplasmic translocation of nuclear KDM1A in a human hepatoma-derived cell line. Immunofluorescence studies revealed cytoplasmic localization of KDM1A, 3 h after addition of GGA or tranylcypromine in HuH-7 cells. Geranylgeraniol and all-trans retinoic acid were both unable to induce translocation of nuclear KDM1A, whereas farnesoic acid showed the weak activity. Furthermore, GGA did not affect subcellular localization of another histone lysine-specific demethylase, KDM5A. This suggests that the inhibitor-induced translocation of nuclear KDM1A to the cytoplasm is specific for KDM1A. These data demonstrate for the first time that KDM1A inhibitors specifically induce the cytoplasmic translocation of nuclear KDM1A.\n\nAbbreviations
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Geldanamycin inhibits Jumonji histone lysine demethylase KDM4 and targets chimeric transcription factor PAX3-FOXO1
A. Abu-Zaid, S. Singh, … J. YANG·bioRxiv·Dec 11, 2019
- Dual targeting of KDM1A and antioxidants is an effective anticancer strategy
Shaila Mudambi, Megan E. Fitzgerald, … György Paragh·bioRxiv·Jun 12, 2024
- LSD1 inhibition corrects dysregulated MHC-I and dendritic cells activation through IFNγ-CXCL9-CXCR3 axis to promote antitumor immunity in HNSCC
Amit Kumar Chakraborty, Lina Kroehling, … Manish V. Bais·bioRxiv·Mar 17, 2025
- KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas
J. A. Heward, L. Koniali, … J. Fitzgibbon·bioRxiv·Jun 30, 2020
- Anti-proliferative effect of potential LSD1/CoREST inhibitors based on molecular dynamics model for treatment of SH-SY5Y neuroblastoma cancer cell line
Hiba M. Zalloum, Waleed A. Zalloum, … Malek Zihlif·Asian Pacific Journal of Cancer PreventionPeer-reviewed·Oct 1, 2022
- LSD1 inhibitors induce neuronal differentiation of Merkel cell carcinoma by disrupting the LSD1-CoREST complex and activating TGFβ signaling
L. Leiendecker, P. S. Jung, … A. C. Obenauf·EMBO Molecular MedicinePeer-reviewed·Oct 7, 2020